Jacobio Pharmaceuticals Group Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

SEHK:1167 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
19 Sep 25	SellHK$5,714,983	CITIC Securities International Asset Management Ltd.	Company	540,000	HK$10.58
18 Sep 25	BuyHK$83,611,875	Yinxiang Wang	Individual	9,501,350	HK$8.80
18 Sep 25	SellHK$92,411,874	Gloryviewpharma Ltd	Company	10,501,350	HK$8.80
03 Sep 25	BuyHK$2,103,923	Yinxiang Wang	Individual	209,100	HK$10.06
02 Sep 25	BuyHK$1,974,382	Yinxiang Wang	Individual	192,300	HK$10.27
01 Sep 25	BuyHK$4,866	Yinxiang Wang	Individual	600	HK$8.11
26 Aug 25	SellHK$47,220,012	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	Company	6,000,000	HK$7.87
18 Aug 25	SellHK$58,479,989	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	Company	8,000,000	HK$7.31
07 Aug 25	SellHK$9,023,680	CITIC Securities International Asset Management Ltd.	Company	1,223,400	HK$7.38
29 Jul 25	BuyHK$15,864	Yinxiang Wang	Individual	2,100	HK$7.55
25 Jul 25	BuyHK$30,156	Yinxiang Wang	Individual	4,200	HK$7.18
24 Jul 25	BuyHK$389,904	Yinxiang Wang	Individual	54,600	HK$7.14
22 Jul 25	BuyHK$1,564,481	Yinxiang Wang	Individual	221,100	HK$7.08
21 Jul 25	BuyHK$128,142	Yinxiang Wang	Individual	18,900	HK$6.78
18 Jul 25	BuyHK$1,335,061	Yinxiang Wang	Individual	215,100	HK$6.21
17 Jul 25	BuyHK$440,503	Yinxiang Wang	Individual	77,100	HK$5.71
16 Jul 25	BuyHK$3,044,484	Yinxiang Wang	Individual	562,200	HK$5.42
23 May 25	SellHK$5,916,862	Hillhouse Investment Management, Ltd.	Company	1,225,200	HK$4.83
20 Jan 25	SellHK$3,938,349	Qiming Weichuang Venture Capital Management (Shanghai) Company Limited	Company	2,669,699	HK$1.48
10 Dec 24	SellHK$234,562	Qiming Weichuang Venture Capital Management (Shanghai) Company Limited	Company	161,700	HK$1.45
28 Nov 24	SellHK$145,275	Qiming Weichuang Venture Capital Management (Shanghai) Company Limited	Company	92,958	HK$1.56
07 Oct 24	BuyHK$5,784	Yinxiang Wang	Individual	2,400	HK$2.41

Insider Trading Volume

Insider Buying: 1167 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1167?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	8,500,000	1.08%
Employee Share Scheme	26,806,765	3.4%
VC/PE Firms	46,734,925	5.93%
Public Companies	87,486,890	11.1%
Institutions	120,067,954	15.2%
Individual Insiders	164,850,520	20.9%
General Public	334,177,826	42.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 17 shareholders own 57.63% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15%	Yinxiang Wang	118,613,125	HK$1.2b	10.3%	no data
11.1%	Center Laboratories, Inc.	87,486,890	HK$859.1m	0%	no data
5.93%	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	46,734,925	HK$458.9m	-23.1%	2.92%
4.99%	Hillhouse Investment Management, Ltd.	39,343,510	HK$386.4m	-17.1%	0.39%
4.99%	CITIC Securities International Asset Management Ltd.	39,339,900	HK$386.3m	0%	63.97%
4.86%	Qiming Weichuang Venture Capital Management (Shanghai) Company Limited	38,327,644	HK$376.4m	0%	2.75%
2.95%	Yunyan Hu	23,292,295	HK$228.7m	0%	no data
2.91%	Xiaojie Wang	22,945,100	HK$225.3m	0%	no data
2.41%	Willgenpharma LImited	19,035,835	HK$186.9m	0%	no data
1.08%	Blesspharma Ltd	8,500,000	HK$83.5m	0%	no data
0.99%	Gloryviewpharma Ltd	7,770,930	HK$76.3m	-57.5%	no data
0.16%	GF Fund Management Co., Ltd.	1,299,300	HK$12.8m	0%	no data
0.13%	Caitong Fund Management Co., Ltd.	1,039,200	HK$10.2m	0%	0.05%
0.052%	China Universal Asset Management Company Ltd.	413,700	HK$4.1m	0%	no data
0.027%	State Street Global Advisors, Inc.	210,300	HK$2.1m	197%	no data
0.012%	Dimensional Fund Advisors LP	94,000	HK$923.1k	0%	no data
0.00005%	Norges Bank Investment Management	400	HK$3.9k	0.25%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/29 18:14
End of Day Share Price	2025/09/29 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jacobio Pharmaceuticals Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyi Chen	Goldman Sachs